• Andrew Carr, Ph.D., Independent Consultant
• Rajen Dalal, Ph.D., Chief Executive Officer of Aviir
• Jutta Heim, Ph.D., Chief Scientific Officer, Basilea Pharmaceutica Ltd.
• Al Kolb, Ph.D., Consultant, KeyTech Solutions
• Andreas Manz, Ph.D., Director, ISAS Dortmund
• André Marion, Director, Labcyte, Guava Technologies, Singulex, Inc.
• Philippe Renaud, Ph.D., Director, CMI at EPFL

Andrew Carr, Ph.D., Independent Consultant
Andrew Carr holds Chairman and non executive director positions on the Boards of Teraview Ltd, deltaDOT Ltd and Akubio Ltd and is a partner in SciBridge Limited, a business advisory group. He was previously Chief Executive Officer of Amersham Biosciences and a Board Director of Amersham plc, a global leader in diagnostics and life science research which was acquired by GE in 2005. He has a B.Sc in Biology and a Ph.D in Zoology from the University of Nottingham, England. «back to top»

Rajen Dalal, Ph.D., Chief Executive Officer of Aviir
Since October 2006, Rajen Dalal has served as Chief Executive Officer of Aviir, Inc., a molecular diagnostics company. From 2002 to 2005, he was the President and Chief Executive Officer of Guava Technologies, Inc., a biotechnology company based on mammalian cell profiling and analysis. Prior to joining Guava, Dr. Dalal was at Chiron Corporation, where he was most recently President of its Blood Testing Division. Prior to joining Chiron in 1991, Dr. Dalal was a leader of McKinsey & Company’s pharmaceuticals and technology management groups. Dr. Dalal received a B.Sc. in chemistry from St. Xavier’s College, University of Bombay, India, an M.Sc. in biochemical engineering from the Massachusetts Institute of Technology and an M.B.A. from the University of Chicago, in the US. «back to top»

Jutta Heim, Ph.D., Chief Scientific Officer, Basilea Pharmaceutica Ltd.
Jutta Heim is Chief Scientific Officer of Basilea Pharmaceutica Ltd., a biopharmaceutical company headquartered in Switzerland. Prior to this appointment she worked for more than 20 years in Switzerland and in the United States for Ciba-Geigy/Novartis Pharma AG in various positions with increasing management responsibility. In the Ciba-Geigy Biotechnology department, she was involved in the successful development and launch of biopharmaceutical antithrombotic and fibrinolytic products. At Novartis she initiated a Molecular Genetics department in oncology, prior to becoming the company’s Senior Scientific Expert in Molecular Biology and member of the Research Management Board. Her responsibilities included scientific chairmanship of the Novartis-Vertex kinase collaboration, of the Functional Genomics Net, as well as leadership of the central Novartis Lead Discovery Center with worldwide screening responsibilities. At Basilea she is responsible for the global discovery effort of new antibacterial, antifungal and anticancer drugs as well as for dermatological disease-modifiers. Dr. Heim holds a professorship in Biotechnology at the Biocenter of the University of Basel and is on the Board or the Scientific Advisory Board of several biotech companies. «back to top»

Al Kolb, Ph.D., Consultant, KeyTech Solutions
Al Kolb operates his own consulting company, KeyTech Solutions, which focuses on the identification, development and commercialization of drug discovery technologies. Currently, he serves as Past President of the Society for Biomolecular Screening, of which he is one of the founders. He is a member of the Board of Scientific Advisors for the MipTec conference and serves on the editorial boards of the Journal for Biomolecular Screening and Current Drug Discovery Technologies. He has been involved in high-throughput screening since the late 1980s, with Beckman, Packard and several other instrument and automation companies. His projects have included the development of microplates (scintillating, filter bottom and clear bottom plates), assay technologies (luminescent reporter and cytotoxicity assays, HTRF, ALPHA), micro-plate readers (TopCount, Discovery, AlphaQuest) and large scale automation systems. He was involved in the early development of instruments and applications for miniaturization including 384- and 1536-well plates, nanoliter dispensing, imaging and labchip technologies. He received his Ph.D. from the University of California, Irvine, in Molecular Biology and Biochemistry and completed a post-doctoral fellowship at the Roche Institute for Molecular Biology in the US. «back to top»

Andreas Manz, Ph.D., Director, ISAS Dortmund
Andreas Manz is one of the pioneers in microchip technology used for chemical applications. He was involved in the development of high-speed analysers based on capillary electrophoresis, liquid chromatography and flow-injection analysis. These analysers benefit from the micro-fabrication know-how originally developed for microelectronics, from the small volumes obtainable, and from the high degree of integration. He did most of his previous research with his group at Ciba-Geigy Ltd. in Basel, Switzerland, and at Imperial College in London, United Kingdom. Andreas Manz developed a novel concept for Miniaturized Total Analysis Systems (µ-TAS): sampling, sample pre-treatment, separation, and detection steps are all performed in an integrated microsystem. «back to top»

André Marion, Director, Labcyte, Guava Technologies, Singulex, Inc.
André F. Marion retired from the Perkin-Elmer Corporation as the President of its Applied Biosystems Division on February 1, 1995. Mr. Marion was the Chairman of the Board, Chief Executive Officer, and President of Applied Biosystems, Inc. at the time of its merger with Perkin-Elmer in 1993. As one of the founders of Applied Biosystems, Inc., André Marion served as the company’s Chairman of the Board from October 1987, and, from end February 1990, once again took up his positions as President and Chief Executive Officer, which he had held earlier from 1986 to 1989. Between January 1985 and October 1988, he was the President of the company, after serving respectively as its Chief Operating Officer and its Vice President of Engineering from the founding year of the company in 1981. Mr. Marion held various Research and Development managerial positions during his employment with the Hewlett-Packard Corporation from 1972 to 1981. André Marion holds an engineering degree from the French Ecole Nationale Supérieures d'Ingénieurs Arts et Métiers in both mechanical and electronic engineering. He is the holder of several U.S. patents related to printing, data processing and storage. Mr. Marion currently serves as Director of several private corporations. «back to top»

Philippe Renaud, Ph.D., Director, CMI at EPFL
Philippe Renaud joined the Swiss Federal Institute of Technology (EPFL) in 1993 and was appointed full Professor in 1997. His current research interests include microsystem design, micro-fabrication technologies for micro-sensor applications and microfluidics, and biomicrosystems applications. He is also Director of the EPFL Centre of Microtechnology (CMI), a large clean-room facility with processing equipment for training and scientific experimentation in microelectronic and micro-fabrication processes. Since 1996, he has been Chairman and organizer of the international Nanotech Conference on Micro- and Nano-technologies for Biosciences. Prior to joining EPFL, Professor Philippe Renaud worked in the Sensors and Actuators group at the Swiss Centre for Electronics and Microtechnology (CSEM) in Neuchâtel, Switzerland. He received his Diploma in physics from the University of Neuchâtel and his Ph.D. from the University of Lausanne, Switzerland. He conducted his post-doctoral research at the University of California, Berkeley, USA, and then at the IBM Zürich Research Laboratory in Switzerland. «back to top»